Cargando…
Testing preexisting antibodies prior to AAV gene transfer therapy: rationale, lessons and future considerations
Given the increasing number of gene transfer therapy studies either completed or underway, there is growing attention to the importance of preexisting adaptive immunity to the viral vectors used. The recombinant viral vectors developed for gene transfer therapy share structural features with natural...
Autores principales: | Mendell, Jerry R., Connolly, Anne M., Lehman, Kelly J., Griffin, Danielle A., Khan, Sohrab Z., Dharia, Sachi D., Quintana-Gallardo, Lucía, Rodino-Klapac, Louise R. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society of Gene & Cell Therapy
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8933338/ https://www.ncbi.nlm.nih.gov/pubmed/35356756 http://dx.doi.org/10.1016/j.omtm.2022.02.011 |
Ejemplares similares
-
Expression and function of four AAV-based constructs for dystrophin restoration in the mdx mouse model of Duchenne muscular dystrophy
por: Potter, Rachael A., et al.
Publicado: (2023) -
AAV1.NT-3 Gene Therapy for Charcot–Marie–Tooth Neuropathy
por: Sahenk, Zarife, et al.
Publicado: (2014) -
Homologous Recombination Mediates Functional Recovery of Dysferlin Deficiency following AAV5 Gene Transfer
por: Grose, William E., et al.
Publicado: (2012) -
AAV.Dysferlin Overlap Vectors Restore Function in Dysferlinopathy Animal Models
por: Sondergaard, Patricia C, et al.
Publicado: (2015) -
Current Clinical Applications of In Vivo Gene Therapy with AAVs
por: Mendell, Jerry R., et al.
Publicado: (2021)